Malaria, Falciparum Clinical Trial
Official title:
A Proof-of-concept Study to Assess the Effect of MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants.
A single-centre, open-label, study using induced blood stage malaria infection to characterize the activity of MMV390048 against early Plasmodium falciparum blood stage infection.
Study using induced blood stage malaria infection to characterize the activity of MMV390048
against early Plasmodium falciparum blood stage infection. There will be two or more cohorts
of 8 subjects. In the first cohort a single dose of 20 mg of MMV390048 will be investigated.
Depending on the data obtained, the dose in Cohort 2 may be adjusted but will not exceed the
maximum tolerated dose (or highest achieved dose based on a predefined exposure cap) as
determined in an ongoing single ascending dose study. Each participant will be inoculated on
Day 0 with ~1,800 viable parasites of Plasmodium falciparum-infected human erythrocytes
intravenously. On an outpatient basis, participants will be monitored daily until positive
for presence of malaria parasites. Once positive they will be monitored twice-daily until
treatment, for adverse events and the unexpected early onset of symptoms, signs or
parasitological evidence of malaria. On the day designated for commencement of treatment,
participants will be admitted to the study unit and monitored. The threshold for commencement
of treatment will be when quantification of all participants is ≥ 1,000 parasites/mL. If the
quantification of any participant is ≥ 5,000 parasites/mL, and is accompanied by a clinical
symptom score >5, or if clinical or parasitological evidence of malaria occurs in any
participant before all participants have reached the treatment threshold (quantification of ≥
1,000), then treatment of that participant will begin within a 24 h period.
Following treatment with MMV390048, participants will be followed up as inpatients for at
least 72 hours to ensure tolerance of the treatment and clinical response, then on an
outpatient basis if clinically well for monitoring of safety and clearance of malaria
parasites. Compulsory treatment with Riamet® (artemether-lumefantrine) will start on day 16
(±3 days) post study treatment unless required earlier. Early intervention can occur if
either poor responses or fast responses are seen following MMV390048 treatment. This is to
ensure participant safety and to avoid participant inconvenience if useful data cannot be
obtained. Pre-emptive treatment with Riamet® can commence whenever necessary. Participants
will be treated with a single dose (45 mg) of primaquine (Primacin™) at the end of their
Riamet® treatment if gametocytes are identified, to ensure complete clearance of any
gametocytes present.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02329301 -
Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia
|
N/A | |
Recruiting |
NCT01944189 -
Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics
|
Phase 4 | |
Completed |
NCT01325974 -
Time to Become Negative of Three Rapid Diagnostic Tests for Malaria
|
N/A | |
Terminated |
NCT01442168 -
Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria
|
Phase 1/Phase 2 | |
Terminated |
NCT00374205 -
Randomized Trial on Effectiveness of ACTs in Ghana
|
Phase 4 | |
Completed |
NCT00375128 -
Sporozoite Challenge of Polyprotein Vaccinees
|
Phase 1/Phase 2 | |
Completed |
NCT04609098 -
Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)
|
Phase 2 | |
Completed |
NCT02851108 -
Methylene Blue Against Falciparum Malaria in Burkina Faso
|
Phase 2 | |
Completed |
NCT02434952 -
Safety and Tolerability of Low Dose Primaquine
|
Phase 4 | |
Completed |
NCT01213966 -
Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection
|
Phase 2 | |
Completed |
NCT00479206 -
Artemisinin Resistance in Cambodia
|
N/A | |
Completed |
NCT00126906 -
Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi
|
N/A | |
Completed |
NCT01019408 -
Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan
|
Phase 4 | |
Completed |
NCT00529867 -
Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria
|
Phase 4 | |
Completed |
NCT00137553 -
The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children
|
Phase 4 | |
Completed |
NCT02637128 -
In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria
|
Phase 4 | |
Completed |
NCT01222962 -
Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers
|
Phase 1 | |
Unknown status |
NCT00152204 -
The Community Effectiveness of IPTi in Southern Tanzania
|
Phase 3 | |
Terminated |
NCT00084240 -
Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia
|
Phase 2/Phase 3 | |
Completed |
NCT00137514 -
Chloroquine and Amodiaquine for Treatment of Malaria in Children
|
Phase 4 |